The ability to control T cell reactivity using suicide genes opens new perspectives for the treatment of T cell-mediated diseases. The therapeutic effect is achieved by the selective killing of thymidine kinase gene-modified activated T cells by ganciclovir (GCV). This strategy has been shown to control T cell alloreactivity efficiently after bone marrow or solid organ transplantation. Here, we aimed to determine whether an immunopathological process induced by a viral infection could be controlled by GCV when T cells express a thymidine kinase transgene. When transgenic mice were infected with the lymphocytic choriomeningitis virus, administration of GCV resulted in an efficient, but only transient, control of the immunopathological immune response. Further analysis
Introduction
T cells responding to foreign or self antigens can cause serious pathologies such as graft-versus-host disease, allograft rejection, autoimmune disease or virus-induced immunopathologies that generally are poorly controlled by classical immunosuppression. Gene therapy strategies permitting selective killing of such T cells in vivo would open new therapeutic perspectives.
Suicide genes code for enzymes that render cells sensitive to otherwise non-toxic prodrugs. 1 The prototype suicide gene is the Herpes simplex type 1 thymidine kinase (TK) gene. The TK enzyme converts nucleoside analogs such as ganciclovir (GCV) into the monophosphate form, a pathway not occurring in unmanipulated eukaryotic cells. The monophosphate is in turn transformed into a triphosphate metabolite, a potent inhibitor of DNA elongation causing cell death by apoptosis. 2, 3 Thus, TK gene transfer creates a genetically determined difference between GCV-insensitive TK − or resting TK + cells, and GCV-sensitive dividing TK + cells. Applications of suicide genes include anti-cancer gene therapy [4] [5] [6] -currently under intensive clinical evaluation 7 -and the development of experimental tools to kill dividing cell populations selectively in transgenic (Tg) mice expressing TK under the control of tissue-specific promoters. [8] [9] [10] [11] Correspondence: D Klatzmann, Laboratoire revealed the existence of a minute population of GCV-insensitive T cells. These cells expand in response to the virus despite the presence of GCV and cause immunopathology before viral elimination is finally obtained. Thus, when confronted with a replicative virus, the efficacy of this genetic immunosuppression strategy is highly dependent on the presence of even small numbers of GCV-insensitive cells. These results emphasize the need for sufficient preclinical investigations with regard to the pathology and the nature of the immune response if suicide gene transfer is envisioned for new therapeutic indications. Gene Therapy (2000) 7, 1536-1542.
Since T cells activated by target antigens subsequently undergo cell division, suicide genes are particularly well suited for developing new immunotherapy approaches which aim to eliminate antigen-responsive proliferating T cells engaged in pathological immune responses. The proof of this concept is provided by preclinical studies showing that, after allogeneic bone marrow (BM) transplantation, graft-versus-host disease can be controlled by a short GCV treatment provided that donor T cells express TK. 12, 13 This strategy is now under clinical evaluation [14] [15] [16] [17] with the use of retrovirus-mediated T cell gene transfer. [18] [19] [20] Recently, the TK/GCV system has also proved efficient in preventing rejection of vascularized allogeneic heart transplantation in mice. 21 To date, the efficacy of T cell-mediated suicide gene therapy has only been demonstrated for immunomodulation of alloreactivity. Nevertheless, this approach can potentially be effective on any type of T cell response involving dividing T cells. Therefore, we aimed to determine whether an immunopathological process induced by a viral infection could be controlled by GCV when T cells express TK.
Infection with the non-cytopathic lymphocytic choriomeningitis virus (LCMV) represents a paradigm of virusinduced T cell-mediated diseases. [22] [23] [24] Indeed, there is a high frequency of LCMV-specific cells in the T cell repertoire, reaching 10% of all T cells during acute infection. 25 After intracerebral (i.c.) infection with LCMV, immunocompetent mice die within 6-7 days due to choriomeningitis secondary to the recruitment of cytotoxic T cells (CTLs) and inflammatory cells within the leptomen-ingeal spaces. [26] [27] [28] This anti-LCMV immune response is dependent on the presence of T cells 29 and, notably, on the activation of major histocompatibility (MHC) class Irestricted CD8 T cells 30, 31 whereas MHC class II-restricted CD4 T cells are not mandatory. [32] [33] [34] Interestingly, the anti-LCMV response can be monitored by using a non-lethal route of inoculation. For instance, when using intraplantar (i.pl.) inoculation, it is possible to determine the kinetics of the DTH response by measuring footpad swelling whose peak correlates with the peak of CTLs. [35] [36] [37] In this study, we determined whether a GCV treatment could control the immunopathology occurring after LCMV infection in mice expressing TK in their T cells. For this purpose, we used transgenic mice expressing the TK gene 38 under the transcriptional control of CD4-derived regulatory sequences driving in vivo expression in T cells. 39 
Results
Later onset of delayed-type hypersensitivity after LCMV footpad infection We investigated the possibility of controlling a virusmediated immunopathology by specific elimination of dividing T cells responding to LCMV. For this, we first used a non-lethal route of LCMV infection. This allowed us to monitor the DTH response to LCMV by measuring footpad swelling after i.pl. inoculation, and to study viral elimination and specific anti-LCMV antibody response. Non-Tg mice mounted a typical DTH response with a peak at day 6, regardless of the presence of GCV ( Figure  1a ). Similar kinetics of DTH were observed in TK-Tg mice not receiving GCV, indicating that TK expression in T cells does not impair the antiviral T cell response ( Figure  1b) . When TK-Tg mice were treated with GCV up to day 6, the anti-LCMV DTH response was blocked from day 5 to day 7 (P Ͻ 0.005). Nevertheless, this blockade was not lasting since footpad swelling subsequently developed with a peak at day 9. Thus, a 7 day GCV treatment efficiently but transiently blocked the anti-LCMV T cell response with a 3 day delay in the DTH peak.
Viral elimination
Complete blockade of the T cell response to LCMV should lead to incapacity of mice to clear the virus as observed in T cell-deficient mice [29] [30] [31] 33 and thus, to a virus carrier state. Alternatively, the maintenance of a T cell response -even if delayed -should allow complete viral elimination. We therefore investigated the viral state of GCV-treated TK-Tg mice. At day 21 after the viral challenge, GCV-treated TK-Tg mice had completely eliminated LCMV (Table 1) , suggesting the presence of anti-LCMV CTLs despite GCV treatment. Furthermore, treated mice produced normal titers of anti-LCMV IgG antibodies (Table 1) , suggesting anti-LCMV CD4 T cell/B cell co-operation. Thus, despite the delay in the DTH response, GCV-treated TK-Tg mice remained immunocompetent, cleared the virus and produced specific IgG antibodies.
Prolongation of survival after LCMV i.c. infection
We also investigated the possibility of controlling the lethal choriomemingitis occurring after LCMV i.c. inoculation. At a dose of 10 4.2 p.f.u. of LCMV, all control mice
Gene Therapy died with clinical signs of choriomeningitis including weight loss, hair ruffling and characteristic central nervous system disease. Their mean survival was 5.8 days (Figure 2a ). When TK-Tg mice were treated with GCV for 7 days, a statistically significant prolongation of survival was observed. The average gain in survival between control and treated groups was 2.3 days. The absence of complete protection was not due to the dose of virus since similar results were found when using a lower LCMV inoculum of 10 2.5 p.f.u. (Figure 2b ). These data indicate that a 7 day GCV treatment prolongs survival of TK-Tg mice infected with a lethal dose of LCMV but does Transfer of GCV sensitivity through syngeneic bone marrow transplantation To evaluate whether the suicide gene-mediated modulation of the anti-LCMV T cell response could be transferred to non-transgenic mice, we performed BM transplantation experiments. For this, lethally irradiated FVB mice were grafted with a BM transplant from syngeneic TK-Tg mice. At 3 months after transplantation, BM chimeras were infected with LCMV. After i.c. infection, all chimeras not receiving GCV died from choriomeningitis (Figure 3a) . After footpad infection, chimeras not receiving GCV exhibited a significant anti-LCMV DTH response (Figure 3b ). Whatever the route of infection, the kinetics of the response were similar to that of ungrafted GCV-treated TK-Tg mice (Figures 1a, 2a) , indicating a good immune reconstitution of BM chimeras.
Figure 1 GCV treatment of TK-transgenic mice results in a delay in DTH to LCMV after footpad injection. Mice were infected in the hind footpad with 10 4.2 p.f.u. of LCMV. Results are expressed as the difference of thickness between the infected and non-infected footpads (mean ± s.e.m.). Arrow indicates last GCV injection. (a) DTH curves of LCMV-infected non-transgenic FVB mice which had received PBS (n = 10, open circles) or GCV (n = 12, closed circles) from day 0 (LCMV inoculation) to day 6 included. ANOVA: non-Tg/PBS versus non-Tg/GCV d0-6 (NS). (b) DTH curves of LCMV-infected TK-transgenic mice which had received PBS (n = 4, open circles) or GCV (n = 13, closed circles) from day 0 to day 6 included, or from day 0 to day 13 included (n = 5, black squares). ANOVA: TK-Tg/PBS versus TK-Tg/GCV d0-6 (P Ͻ 0.0001); TKTg/PBS versus TK-Tg/GCV d0-13 (P Ͻ 0.0001) ; TK-Tg/GCV d0-6 versus TK-Tg/GCV d0-13 (NS). Mann-Whitney test: TK-Tg/PBS versus TK-Tg/GCV d0-6 (*P Ͻ 0.005; otherwise, NS).

Table 1 Viral clearance and anti-LCMV IgG production
Figure 2 GCV treatment prolongs survival of TK-transgenic mice after intracerebral injection of a lethal dose of LCMV. (a)
When treated with GCV for 7 days, BM chimeras showed a statistically significant prolongation of survival (Figure 3a) . The average gain in survival between control and treated groups was 2.4 days, almost identical to that observed with ungrafted TK-Tg mice. In addition, at day 6 and day 7 following LCMV i.pl. infection, the DTH response of the chimeras was significantly reduced (P Ͻ 0.05) as compared with controls (Figure 3b) . At day 21 after infection, all mice had eliminated the virus and had produced high titers of anti-LCMV IgG antibodies (Table  1) . Together, these data indicate that suicide genemediated modulation of the anti-LCMV T cell response is transferable to non-Tg mice by syngeneic BM transplantation.
Recruitment of GCV-insensitive CD8 T cells
The duration of GCV administration in the previous experiments was 7 days. It was, therefore, possible that the mortality which occurred around day 8 after i.c. infection and the DTH peak observed at day 9 in GCV-treated TK-Tg mice might reflect an insufficient duration of GCV treatment. To test this hypothesis, TK-Tg mice were infected i.c. with LCMV and treated with GCV for 14 days or until death. This prolongation of GCV treatment had almost no effect on survival as compared with the 7 day treatment (Figure 2b) . Similarly, when LCMV was inoculated by the i.pl. route, TK-Tg mice treated with GCV for 14 days exhibited DTH kinetics almost indistinguishable from those of mice treated for 7 days ( Figure  1b) . Thus, the anti-LCMV T cell response in TK-Tg mice is efficiently controlled by GCV up to day 7. The delayed mortality and DTH response suggest the recruitment of GCV-insensitive T cells.
Frequency of GCV-insensitive T cells
We next aimed to determine the frequency of GCV-insensitive TK-Tg T cells before LCMV infection. For this, we performed limiting dilution analysis of T cells from TKTg mice in response to the T cell mitogen concanavalin A (ConA), in the absence or presence of GCV. In CD4-enriched TK-Tg spleen cells, the frequency of cells which could divide -and thus incorporate 3 H-thymidine -in response to ConA despite the presence of GCV was 70-fold lower than that observed in the absence of GCV (Figure 4) . Thus, although a vast majority of cells was sensitive to GCV, 1.4% of CD4 T cells present in the spleen of TK-Tg mice was insensitive to the nucleoside analog. In CD8-enriched TK-Tg spleen cells, this frequency was slightly higher, with 2.1% of T cells dividing despite the presence of GCV. Therefore, in TK-Tg mice, there exists a minute population of T cells which are not sensitive to GCV.
Characterization of the GCV-insensitive T cell population
Since CD8 T cells account for the DTH peak after LCMV footpad injection of unmanipulated mice 31, 33 and GCVinsensitive cells seemed to predominate in the CD8 compartment, we next investigated whether the delayed DTH peak observed at day 9 in GCV-treated TK-Tg mice was due to CD8 or to CD4 T cells. For this, we injected depleting anti-CD4 or anti-CD8 monoclonal antibodies in vivo at the end of GCV treatment, just before the onset of the GCV-insensitive DTH peak. Anti-CD4 treatment was unable to prevent the occurrence of a delayed DTH peak in GCV-treated TK-Tg mice ( Figure 5 ). In contrast, antiGene Therapy
Figure 4 Determination of the frequency of GCV-insensitive T cells in TK-Tg mice. The ConA responder frequency was determined by limiting dilution analysis in CD4-and CD8-enriched spleen cells from TK-Tg animals. Experiments were performed in the absence or presence of GCV. Responder frequency corresponding to 37% negative wells is indicated together with correlation coefficients.
CD8 treatment completely abolished the DTH response otherwise observed at day 8 and day 9 (P Ͻ 0.05). Thus, the delayed anti-LCMV T cell response observed in GCVtreated TK-Tg mice is secondary to the emergence of GCV-insensitive CD8 T cells. Together, these data indicate that genetic immunosuppression can efficiently but only transiently control LCMV-induced immunopathology.
Discussion
We investigated the possibility of using genetic immunosuppression to control the immunopathological immune response induced by LCMV. This approach relies on the specific elimination of T cells engaged in the cell cycle, a situation occurring when T cells are activated after encounter with antigen. The results of this study showed that a GCV treatment efficiently, but only transiently, blocked the anti-LCMV T cell response in mice expressing TK in mature T cells. After i.c. infection, a GCV treatment led to an approximately 40% increase in the duration of survival but no long-term survivors were observed. After i.pl. inoculation, GCV administration resulted in the complete blockade of footpad swelling during the interval where untreated mice exhibited a patent DTH. Nevertheless, after day 7, DTH finally occurred with a profile similar to that observed in the absence of GCV. As opposed to T cell-deficient mice which cannot control LCMV replication, 29, 31 the delayed antiviral response was fully efficient since all mice cleared the virus and produced normal amounts of specific IgG antibodies.
Since the peak of DTH in FVB mice occurs at day 6, a 7 day GCV treatment should have been sufficient to kill all activated anti-LCMV T cells in their phase of clonal expansion. Two main hypotheses can be advanced to explain the escape of the DTH response. On the one hand, some anti-LCMV T cells may start dividing only after day 6, at a time when GCV is no longer present due to its short half-life. 40, 41 On the other hand, the delayed DTH response may be due to the recruitment of pre-existing GCV-insensitive T cells that would proliferate despite the presence of GCV and yield a quantitatively similar but delayed DTH response. To test this alternative, we first prolonged the GCV treatment beyond the time of maximal DTH response. Whatever the route of LCMV inoculation, a prolonged GCV treatment had an almost identical effect on the DTH response as a 7 day treatment. This result supports the second hypothesis concerning recruitment of GCV-insensitive T cells. This hypothesis is further supported by limiting dilution experiments that demonstrated the existence of a small population, ie approximately 1-2% of T cells, that could incorporate thymidine despite the presence of GCV. These GCVinsensitive T cells were slightly more frequent in the CD8 than in the CD4 compartment. In addition, an anti-CD8 antibody treatment abolished the delayed DTH peak whereas anti-CD4 had no effect. Consequently, the 3 day delay observed in the DTH response presumably reflects the time needed for a few pre-existing GCV-insensitive anti-LCMV T cells to proliferate and reach a number sufficient to induce a DTH response quantitatively equivalent to that observed around day 6 in non-Tg mice. A likely explanation for GCV insensitivity would be the absence of TK expression in a minority of T cells due to position-effect variegation, a phenomenon by which a transgene integrated within or in the vicinity of centromeric heterochromatin is inactivated in some target cells. [42] [43] [44] The TK/GCV system has considerable potential in clinical medicine. Its versatility has been outlined 45 and the modalities of the treatment can significantly influence its outcome. 46 In the case of graft-versus-host disease, the therapeutic goal is to control a defined number of adoptively transferred T cells. The efficacy of elimination of dividing T cells is clearly sufficient to reduce the alloreactive T cell pool below the threshold required to elicit graft-versus-host disease. 12, 13, 15, 45, 47 Although the indications of T cell suicide gene strategies can theoretically extend to any type of immunopathology involving dividing T cells, the present study illustrates that the nature of the antigen is a critical factor for its success. When a small proportion of GCV-insensitive T cells is confronted with a replicative virus, it is likely that there is a continuous recruitment of T cells that cause both antigen-driven immunopathology and clearance of LCMV. In the case of solid organ transplantation, the location of the graft is also critical since the survival of an allogeneic heart is only prolonged when implanted subcutaneously whereas it is definitively tolerated when the transplant is vascularized. 21, 48 The development of new applications of T cell suicide gene therapy will, therefore, require intensive preclinical investigations with regard to the pathology, the nature of the immune response and the nature of the antigen. Since the best currently available methods of retrovirus-mediated gene transfer allow approximately 95% of T cells to be transduced, 49 it can be presumed that a minute population of untransduced T cells will still be present, even after an in vitro selection step. Hence, the present TK-Tg line is a good model to provide information on the maximal attainable effect if ex vivo suicide gene transfer is to be used for new therapeutic purposes.
Materials and methods
Mice FVB mice were obtained from Iffa Credo (L'Arbresle, France). TK-transgenic (Ep-TK line 40, FVB genetic background) mice were described previously, 38 and bred under standard pathogen-free conditions. In these mice, the TK transgene is placed under the transcriptional control of CD4 regulatory sequences to obtain constitutive expression of HSV1-TK in both CD4 and CD8 T cells. 39 Manipulations were performed according to European Economic Community guidelines.
LCMV infection and observation LCMV strain Arm/53b (a gift from MB Oldstone, Scripps Research Institute, La Jolla, CA, USA) was maintained by serial passages on BHK21 cells. Mice were inoculated either i.c. or into the hind footpad with 30 l of viral suspension containing 10 4.2 or 10 2.5 p.f.u. of LCMV. Once infected, they were transferred into negative pressure air boxes. GCV (Roche, Neuilly-sur-Seine, France) was injected by the intraperitoneal route at a dose of 50 mg/kg (200 l) twice daily from day 0 to day 6 or day 13 or until death. Animals infected i.c. were weighed and observed every day. In DTH experiments, footpads were measured up to day 21 using a gauge calliper. Results were expressed as the daily difference, in 1/100 mm, between the infected left hind footpad and the noninfected right one. 50 When required, in vivo depletion of T cell subsets was performed by intraperitoneal injection of 300 g (500 l) of either anti-CD4 (clone GK1.5) or anti-CD8 (clone H35-17.2) purified monoclonal antibody (a gift of C Leclerc, Institut Pasteur, France) daily for 3 days.
Syngeneic bone marrow transplantation Syngeneic BM transplantation was performed as described, unless otherwise stated. 12, 46 Briefly, FVB female mice were lethally irradiated (11 Gy) with a Saturne I (CGR Mev, Buc sur Yvette, France). Donor BM was collected from femurs and tibias of TK-Tg female mice and 10 7 BM cells were injected intravenously into recipients. Viral challenge with LCMV was performed 3 months following BM grafting, to permit hematological reconstitution.
Anti-LCMV IgG ELISA Sera were collected 21 days after LCMV infection and assayed for the presence of anti-LCMV IgG antibodies as described. 51 Briefly, ELISA plates were coated overnight with 1.25 g/ml of LCMV (strain Arm/53b). After saturation, plates were incubated at 37°C for 1 h with 1:100 to 1:12 800 serum dilutions, then washed. IgG were detected by peroxidase-conjugated anti-mouse IgG using tetramethyl benzidine plus H 2 O 2 as substrate. A result was considered as positive when more than 3 standard deviations above the negative control serum at 1:100 dilution.
Detection of LCMV
The presence of LCMV was determined from kidney specimens using an enzyme-linked immunoassay (ELISPOT), as described. 52 Briefly, kidneys were frozen at −80°C, mechanically disrupted, centrifuged, diluted from 1/10 to 1/10000, and added to L929 cells. After a 3 day incubation, infected cells were counted by ELISPOT using murine anti-LCMV IgG followed by peroxidaselabeled anti-mouse IgG and diamino benzidine as substrate. 53 Alternatively, LCMV elimination was determined by RT-PCR, as described. 54 Briefly, kidney RNA were extracted using TRIzol (Life Technologies, Grand Island, NY, USA), reverse transcribed and cDNA were further amplified by PCR using the GPC11 and GPC4 primers.
Limiting dilution assay
Spleen cells were incubated with CD4 or CD8 biotinylated antibodies (Pharmingen, San Diego, CA, USA), washed, and streptavidin microbeads (Miltenyi, Bergisch Gladbach, Germany) were added at a ratio of 10 l/10 7 cells. Separation was performed at a concentration of 2 × 10 8 cells/ml using LS separation columns and a Vario-MACS device (Miltenyi). Enrichment was Ͼ90% for CD4 cells and Ͼ70% for CD8 cells, as determined by flow cytometry. CD4-or CD8-enriched spleen cells were then plated in limiting dilution conditions (48 replicates per Gene Therapy dilution) in flat-bottom 96-microwells containing 4 × 10 5 irradiated (2.5 Gy) syngeneic FVB spleen filler cells, 10 ng/ml murine rIL-2 (R&D Systems, Minneapolis, MN, USA), 5 g/ml ConA (Sigma, St Louis, MO, USA). Experiments were performed in the absence or presence of 10 M GCV, a concentration 100-fold higher than the in vitro IC 50 determined previously. 38 After 7 days of culture at 37°C under 5% CO 2 , the number of positive wells was scored by 3 H-thymidine incorporation (1 Ci per well). A well was considered as positive when more than 3 standard deviations above the mean c.p.m. of irradiated filler cells alone. Results fit to the first term of Poisson's distribution and the frequencies were derived from semi-log plots to indicate the number of cells per culture at which 37% of the cultures failed to proliferate. The frequency of responding cells was determined using the Limiting Dilution Analysis software (Oxford University Press, New York, USA).
Statistical analyses
Statistical analyses were performed using Statview software (Abacus Concepts, Berkeley, CA, USA). Analysis of survival was performed by the Kaplan-Meier method. The Mann-Whitney test was used to compare daily footpad swelling values. The PLSD Fisher test was used for analysis of variance (ANOVA).
